Raymond James Financial Inc. Makes New Investment in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Raymond James Financial Inc. purchased a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,765,593 shares of the company's stock, valued at approximately $38,914,000. Raymond James Financial Inc. owned 0.16% of Teva Pharmaceutical Industries as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Farther Finance Advisors LLC raised its position in shares of Teva Pharmaceutical Industries by 273.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company's stock valued at $82,000 after buying an additional 3,323 shares in the last quarter. Atria Investments Inc increased its stake in Teva Pharmaceutical Industries by 135.4% in the third quarter. Atria Investments Inc now owns 30,856 shares of the company's stock valued at $556,000 after acquiring an additional 17,746 shares during the last quarter. Venturi Wealth Management LLC acquired a new position in Teva Pharmaceutical Industries during the third quarter valued at approximately $60,000. WCM Investment Management LLC bought a new stake in Teva Pharmaceutical Industries during the third quarter worth $1,051,000. Finally, Victory Capital Management Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 1.1% in the 3rd quarter. Victory Capital Management Inc. now owns 1,928,715 shares of the company's stock valued at $34,755,000 after purchasing an additional 21,764 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Remove Ads

Teva Pharmaceutical Industries Trading Up 0.1 %

TEVA stock traded up $0.02 during midday trading on Thursday, hitting $16.50. The stock had a trading volume of 14,889,166 shares, compared to its average volume of 13,099,722. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The firm has a market cap of $18.70 billion, a P/E ratio of -11.38, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The business has a fifty day moving average price of $18.47 and a two-hundred day moving average price of $18.32. Teva Pharmaceutical Industries Limited has a 1-year low of $12.51 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Roberto Mignone sold 286,000 shares of the company's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares of the company's stock, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.55% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

TEVA has been the subject of several recent analyst reports. UBS Group dropped their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Barclays dropped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Friday, March 7th. Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. Finally, Bank of America reduced their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of "Moderate Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.